Xeris Biopharma Holdings, Inc. Common Stock (XERS)
PHARMACEUTICAL PREPARATIONS
Xeris Biopharma Holdings, Inc. Common Stock (XERS) is listed on Nasdaq, where it has traded since June 21, 2018.
- Listed On
- Nasdaq
- Listed Since
- June 21, 2018
- Employees
- 435
- Market Cap
- $1.7B
About Xeris Biopharma Holdings, Inc. Common Stock
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 231 institutions reported holding XERS, with 108.0 million shares worth $854.9 million in aggregate. The largest reported holder was BlackRock, with 14.5 million shares worth $115.0 million. Of the 5 largest holders listed below, all 5 added shares during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| BlackRock | 14,525,539 | $115M | Added 12.2% |
| Vanguard | 11,437,150 | $91M | Added 3.97% |
| D. E. Shaw | 7,804,758 | $62M | Added 0.2% |
| State Street | 4,821,566 | $38M | Added 3.51% |
| Geode Capital Management | 4,718,183 | $37M | Added 9.96% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is XERS?
Xeris Biopharma Holdings, Inc. Common Stock (XERS) is listed on Nasdaq, where it has traded since June 21, 2018.
Who are the largest institutional holders of XERS?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of XERS were BlackRock, Vanguard and D. E. Shaw.
How many institutions own XERS?
231 institutions reported a position in XERS for the quarter ended June 30, 2026, worth $854.9 million in total.
Did institutions buy or sell XERS last quarter?
Of the 5 largest reported holders, all 5 added shares during the quarter. Every reported holder and its change is on the SentiSense ownership page for XERS.
Every reported institutional holder, plus insider and congressional trades in XERS, on SentiSense.